株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

シラカバ花粉症:パイプライン分析

Birch Pollen Allergy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200930
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
シラカバ花粉症:パイプライン分析 Birch Pollen Allergy - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 49 Pages
概要

シラカバ花粉アレルギーはシラカバの花粉によって生じる花粉症の一種で、春に原因不明の目・鼻の症状を引き起こします。シラカバ花粉による鼻アレルギーの症状には、風邪やインフルエンザに類似した症状(発熱を伴わないもの)、くしゃみ、喘鳴や呼吸不足による呼吸障害、鼻づまり、結膜炎などが含まれています。通常、抗ヒスタミン剤や非鎮静型抗ヒスタミン剤、アレルギー抑制薬、コルチコステロイド、鼻充血抑制剤などが治療薬として処方されています。

当レポートでは、世界各国での白樺花粉症の治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

シラカバ花粉症の概要

治療薬の開発

  • シラカバ花粉アレルギー向けパイプライン製品:概要
  • シラカバ花粉アレルギー向けパイプライン製品:比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Stallergenes S.A.

治療薬の評価

  • 単剤製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis
  • AllerT
  • Birch-SPIRE
  • BM-31
  • PL-102
  • rBet v1
  • rBet v1-FV
  • STG-210

最新パイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8255IDB

Summary

Global Markets Direct's, 'Birch Pollen Allergy - Pipeline Review, H2 2016', provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
  • The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Birch Pollen Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Birch Pollen Allergy - Overview
  • Birch Pollen Allergy - Therapeutics under Development by Companies
  • Birch Pollen Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Birch Pollen Allergy - Products under Development by Companies
  • Birch Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma GmbH & Co. KG
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Stallergenes SAS
  • Birch Pollen Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AllerT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Birch Pollen Allergoid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-31 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STG-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Birch Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Birch Pollen Allergy - Dormant Projects
  • Birch Pollen Allergy - Discontinued Products
  • Birch Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016
      • Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
      • Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
      • Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
      • Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
      • Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
      • May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
      • Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
      • Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
      • Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT
      • Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT
      • Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT
      • Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment
      • Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
      • Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Birch Pollen Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016
  • Birch Pollen Allergy - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
  • Birch Pollen Allergy - Pipeline by Anergis SA, H2 2016
  • Birch Pollen Allergy - Pipeline by Biomay AG, H2 2016
  • Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016
  • Birch Pollen Allergy - Pipeline by Stallergenes SAS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Birch Pollen Allergy - Dormant Projects, H2 2016
  • Birch Pollen Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Birch Pollen Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top